Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany's Health Reform Law Stumbles Through Parliament

This article was originally published in The Pink Sheet Daily

Executive Summary

Measure will curtail manufacturer latitude on drug pricing, especially for new drugs not shown to have added benefit over existing products.

You may also be interested in...



Novartis Pulls Galvus From Germany After Failed Price Negotiations

Novartis has withdrawn its oral anti-diabetic Galvus from the German market after failing to secure a mutually beneficial price with payers. Galvus is the only drug dropped from reimbursement under a since-repealed policy to assess added benefits of brand drugs marketed before 2011.

Germany’s Vaccine Industry In Danger Of Disappearing, Says GSK

GSK believes detrimental government policies such as reference pricing and tendering in the vaccines sector are threatening this part of the pharmaceutical industry, and patient health.

German Pharma Balks As Second HTA Retrospective Assessment Includes Orphan Drugs

Germany’s senior reimbursement body, the G-BA, has announced it will assess a second wave of older drugs, despite a pending coalition agreement dropping this practice.

Related Content

Topics

UsernamePublicRestriction

Register

PS071432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel